GNMX Aevi Genomic Medicine Inc.

1.21
+0.04  (+3%)
Previous Close 1.17
Open 1.15
Price To Book 5.76
Market Cap 78367927
Shares 64,766,882
Volume 73,458
Short Ratio
Av. Daily Volume 95,001

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due January 2019.
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 1b data due mid-2019.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD
  2. Detailed Research: Economic Perspectives on Gogo, Aevi Genomic Medicine, PBF Energy, SiteOne Landscape Supply, Douglas Dynamics, and Dine Brands Global — What Drives Growth in Today's Competitive Landscape
  3. GNMX: With ASCEND Enrollment Completed, Read-Out Expected In Q1’19
  4. Aevi Genomic Medicine: 3Q Earnings Snapshot
  5. Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update
  6. New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expectations for 2018
  7. Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial
  8. Aevi Genomic Medicine to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  9. Aevi Genomic Medicine Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
  10. Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
  11. GNMX: AEVI Q2 Update: ASCEND Data By Year-End, Enhanced 001 Co-Crystal
  12. Aevi Genomic Medicine Reports Second Quarter 2018 Financial Results and Provides Business Update
  13. Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001
  14. GNMX: ASCEND Will Enroll To N=64, (consistent with initial trial design)
  15. Aevi Genomic Medicine to Present at the The 2018 JMP Securities Life Sciences Conference
  16. Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
  17. GNMX: Development Timelines Intact, Including AEVI-001 Ph2 ADHD Data Expected ~Mid-Year
  18. Aevi Genomic Medicine to Present at the Jefferies 2018 Global Healthcare Conference